Is Buying Azurrx Biopharma Inc (NASDAQ:AZRX) Here Good Idea?

June 20, 2018 - By Henry Gaston

The stock of Azurrx Biopharma Inc (NASDAQ:AZRX) registered an increase of 1.01% in short interest. AZRX’s total short interest was 40,000 shares in June as published by FINRA. Its up 1.01% from 39,600 shares, reported previously. With 20,700 shares average volume, it will take short sellers 2 days to cover their AZRX’s short positions. The short interest to Azurrx Biopharma Inc’s float is 0.68%.

The stock decreased 1.81% or $0.06 during the last trading session, reaching $3.26. About 17,142 shares traded. AzurRx BioPharma, Inc. (NASDAQ:AZRX) has declined 33.33% since June 20, 2017 and is downtrending. It has underperformed by 45.90% the S&P500.

AzurRx BioPharma, Inc., a clinical development stage biopharmaceutical company, engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company has market cap of $54.65 million. The Company’s product pipeline consists of two therapeutic proteins under development, including MS1819, an autologous yeast recombinant lipase, which is in Phase IIa trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, a recombinant b-lactamase combination of bacterial origin for the prevention of hospital-acquired infections, as well as antibiotic-associated diarrhea. It currently has negative earnings.

More important recent AzurRx BioPharma, Inc. (NASDAQ:AZRX) news were published by: which released: “AzurRx Announces Appointment of Dr. James Pennington as Chief Medical Officer” on May 30, 2018, also published article titled: “45 Biggest Movers From Yesterday”, published: “36 Biggest Movers From Friday” on June 11, 2018. More interesting news about AzurRx BioPharma, Inc. (NASDAQ:AZRX) was released by: and their article: “30 Stocks Moving In Friday’s Mid-Day Session” with publication date: June 08, 2018.

AzurRx BioPharma, Inc. (NASDAQ:AZRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.